Virtus Battle Continues Past Due Date
Another twist in the takeover battle for IVF operator Virtus, with private equity firm BGH changing tack yesterday by offering to launch an off-market bid for the company at $8 per share.
Read MoreTag: VRT
Custody Battle Drags on for Virtus Health
The battle for IVF operator Virtus continues, with Australian private equity group BGH upping its offer price to $7.65 per share as it goes head-to-head with London based rival CapVest.
Read MoreBidding War Begins for Virtus Health
London-based private equity firm Cap Vest has overbid local PE group BGH Capital in a new buyout offer for IVF group Virtus Health.
Read MoreCSL Finally Confirms $A16 Billion Vifor Deal
CSL announced late Tuesday that it has struck a deal to buy Swiss-based Vifor Pharma Ltd for $A16.4 billion, its biggest deal since listing in 1994.
Read MoreVRT – Morgans rates the stock as Add
Morgans upgrades the rating to Add from Hold as industry participants have noted a swift recovery for the first quarter FY21. Target price is $5.82.
Read MoreVRT – Morgans rates the stock as Add
Morgans note a strong start to the new year for Virtus Health that has resulted in lower debt and confirmation from the company that the deferred interim dividend from March 2020 will be paid in November 2020.
Read MoreVRT – UBS rates the stock as Upgrade to Buy from Neutral
UBS reviews volume trends for the Australian IVF market and the implications. Data is positive for Virtus Health and the broker updates growth assumptions. Earnings estimates are upgraded by 1-11% across FY19-21.
Read MoreNot So Fertile Ground For IVF Leader
The flagging housing market and sagging consumer sentiment ahead of the federal and NSW elections have affected the performance of an unlikely ASX-listed exponent – the assisted reproduction outfit Virtus Health (VRT, $3.98).
Read MoreIVF Competition Hits Virtus
Shares in Virtus Health plunged by nearly 20% yesterday after the fertility service provider warned falling demand for IVF services and competition from low-cost operators has hit first-half volumes and will affect full-year results without a rebound in demand and profit margins.
Read More
